Skip to main content
ANTEOTECH LTD logo

ANTEOTECH LTD — Investor Relations & Filings

Ticker · ADO ISIN · AU000000ADO8 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,281 across all filing types
Latest filing 2013-08-19 Earnings Release
Country AU Australia
Listing ASX ADO

About ANTEOTECH LTD

https://anteotech.com

AnteoTech Ltd is a surface chemistry company specializing in the development of proprietary nanoglue technology. The company focuses on two primary sectors: life sciences and energy. In the life sciences division, AnteoTech utilizes its AnteoBind molecular linker technology to enhance the performance of point-of-care diagnostic tests, bioprocessing, and assay development by improving the binding of biomolecules to synthetic surfaces. In the energy sector, the company develops advanced materials for lithium-ion batteries, specifically focusing on silicon anodes. Its AnteoX additive is designed to improve the electrochemical performance and structural stability of high-silicon content anodes, addressing capacity loss and cycle life challenges. The company's core value proposition lies in its ability to manipulate surface interfaces at the molecular level to optimize performance in complex chemical and biological environments.

Recent filings

Filing Released Lang Actions
Preliminary Final Report 1 page 17.8KB
Earnings Release Classification · 95% confidence The document is titled 'Appendix 4E, Preliminary Final Report' and contains financial results for the year ended 30 June 2013 compared to the previous year. It includes key financial metrics such as revenue, net loss, dividends, retained earnings, and net tangible assets. The text states that the preliminary final report is based on audited accounts and references the Audit Report contained within the company's 2013 Annual Report. The document is relatively short (2132 characters) and appears to be an announcement of financial results rather than the full annual report itself. Appendix 4E is a regulatory form used in Australia for preliminary final reports, which typically serve as earnings releases or initial financial results announcements. Given the content and length, this document fits best as an Earnings Release (ER) rather than a full Annual Report (10-K) or Audit Report (AR).
2013-08-19 English
Annual Report to shareholders 63 pages 916.5KB
Annual Report Classification · 100% confidence The document is titled 'Annual Report 30 June 2013' for Anteo Diagnostics Limited and contains detailed financial statements, directors' reports, auditor's reports, operating and financial reviews, corporate governance statements, and other comprehensive information typical of a full annual report. The length is substantial (15,000 characters), and the content includes consolidated financial statements and detailed narrative sections. This matches the definition of an Annual Report (10-K) which covers company activity and full financial performance for the fiscal year ending 30 June 2013. There is no indication that this is merely an announcement or a summary, but rather the full report itself.
2013-08-19 English
Quarterly Activities Report Appendix 4C 9 pages 248.9KB
Interim / Quarterly Report Classification · 95% confidence The document is titled as a "CEO Activities Report – Quarter Ended 30 June 2013" and includes detailed operational updates, project progress, intellectual property status, marketing activities, corporate changes, and a financial appendix labeled "Appendix 4C" which is a standard quarterly cash flow report for entities listed on the Australian Stock Exchange. The content is comprehensive and covers multiple aspects of the company's quarterly performance and activities, including financial data such as cash flows and expenditures. The presence of substantive financial data and detailed management commentary for a quarter strongly indicates this is a quarterly report. It is not merely an announcement or a brief summary but a full report with financial statements and operational analysis. Therefore, the document fits the definition of an Interim / Quarterly Report (IR).
2013-07-28 English
Board Room Radio Webcast Commercialisation Grant 1
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 9 July 2013 about Anteo Diagnostics Limited being awarded a $1.7M Early Stage Commercialisation Grant. It mentions a webcast event with a CEO speaker and provides access details for the webcast. The content is a brief announcement of a grant award and webcast, not a detailed financial report, earnings release, or regulatory filing. The document length is short (1001 characters), and it is primarily an announcement of an event and grant award. It does not contain financial statements, management discussion, or detailed investor presentation materials. Therefore, it fits best under Capital/Financing Update (CAP) as it relates to company fundraising or financing activities (grant award).
2013-07-08 English
Anteo awarded $1.7M Early Stage Commercialisation Grant 2 pages 62.9KB
Capital/Financing Update Classification · 95% confidence The document is a company announcement from Anteo Diagnostics Limited regarding the receipt of a $1.7 million grant from Commercialisation Australia. It discusses the purpose of the grant, the project it will fund, and the company's strategy and outlook. There are no financial statements, quarterly or annual results, nor any detailed financial data or regulatory certifications. The document is an update on financing activity related to a government grant, which fits the category of Capital/Financing Update (CAP). The document length is 3658 characters, which is relatively short but contains substantive information about funding, not just an announcement of a report publication. Therefore, it is not a Report Publication Announcement (RPA) or Regulatory Filing (RNS).
2013-06-30 English
European Patent Update 2 pages 122.7KB
Regulatory Filings Classification · 95% confidence The document is a company announcement from Anteo Diagnostics Limited dated 24 June 2013. It discusses the granting of a European patent for the "Use of Metal Complexes" related to their product Mix&Go, along with updates on other patent filings and intellectual property strategy. There is no mention of financial results, management changes, voting results, or regulatory certifications. The content focuses on intellectual property and patent updates, which are typically communicated as regulatory announcements to the stock exchange. The document length is 3732 characters, which is relatively short and reads like an announcement rather than a detailed report. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2013-06-23 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.